Evidence-based pharmacotherapy for personality disorders (Q37841775)

24 August 2017

1 reference

title

Evidence-based pharmacotherapy for personality disorders (English)

1 reference

24 August 2017

0 references

3

Larry J Siever

1 reference

24 August 2017

Joseph Triebwasser

2

1 reference

24 August 2017

Luis H. Ripoll

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21320390

24 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21320390

24 November 2024

publication date

15 February 2011

1 reference

The International Journal of Neuropsychopharmacology

24 August 2017

published in

1 reference

24 August 2017

volume

14

1 reference

24 August 2017

issue

9

1 reference

24 August 2017

page(s)

1257-1288

1 reference

Positron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Moclobemide in social phobia: a controlled dose-response trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Low prolactin response to fenfluramine in impulsive aggression.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Recognition of metaphor and irony in young adults: the impact of schizotypal personality traits

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Risperidone in the treatment of schizotypal personality disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Response to phenelzine among depressed patients with features of hysteroid dysphoria

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Positron emission tomography in female patients with borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

An open, noncomparative study of amoxapine in borderline disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Effects of borderline personality disorder features and a family history of alcohol or drug dependence on P300 in adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Axis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Fluoxetine and Impulsive Aggressive Behavior in Personality-Disordered Subjects

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Anatomical MRI study of borderline personality disorder patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Distinguishing borderline personality disorder from bipolar disorder: differential diagnosis and implications [clinical conference]

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Responding to the emotions of others: dissociating forms of empathy through the study of typical and psychiatric populations

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Theory of mind and its relation to schizotypy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The effects of guanfacine on context processing abnormalities in schizotypal personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The latest neuroimaging findings in borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Fluoxetine in the treatment of borderline and schizotypal personality disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Prolactin response to fenfluramine and suicide attempt lethality in major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The International Personality Disorder Examination. The World Health Organization/Alcohol, Drug Abuse, and Mental Health Administration international pilot study of personality disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

High-risk situations associated with parasuicide and drug use in borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Schizotypy and sustained attention: confirming evidence from an adult community sample

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The effect of docosahexaenoic acid on aggression in elderly Thai subjects--a placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Naltrexone as a treatment of self-injurious behavior--a case report

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Trauma, Genes, and the Neurobiology of Personality Disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Obesity and obesity-related illnesses in borderline patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A developmental, mentalization-based approach to the understanding and treatment of borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The positive effect of alprazolam in the treatment of three patients with borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Impulsivity: a discussion of clinical and experimental findings

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A trial of carbamazepine in borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Discriminating borderline personality disorder from other axis II disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Borderline personality as a self-other representational disturbance

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Reduction by Paroxetine of Suicidal Behavior in Patients With Repeated Suicide Attempts But Not Major Depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The effects of phenytoin on impulsive and premeditated aggression: a controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A controlled trial of phenytoin in impulsive aggression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Predictors of response in generalized social phobia: effect of age of onset

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Empirical Evidence and Psychotherapy: A Growing Scientific Base

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Monoamine metabolites in CSF and suicidal behavior

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The effects of exogenous analgesia in a patient with borderline personality disorder (BPD) and severe self-injurious behaviour

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Paroxetine in social anxiety disorder: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Introduction. Ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Omega-3 fatty acids in the treatment of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Injectable Atypical Antipsychotics for Agitation in Borderline Personality Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Borderline or Bipolar? Distinguishing Borderline Personality Disorder from Bipolar Spectrum Disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Working memory and the syndromes of schizotypal personality

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Interrelationship of Hysteroid Dysphoria and Borderline Personality Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Shape of caudate nucleus and its cognitive correlates in neuroleptic-naive schizotypal personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Avoidant personality disorder: current status and future directions

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The interpersonal dimension of borderline personality disorder: toward a neuropeptide model

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Paradoxical effects of amitriptyline on borderline patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Efficacy of phenelzine and haloperidol in borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Elevated triiodothyronine in psychopathy - possible physiological mechanisms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Is borderline personality disorder part of the bipolar spectrum?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The Collaborative Longitudinal Personality Disorders Study (CLPS): overview and implications

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Self-mutilation in personality disorders: psychological and biological correlates

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The pathophysiology of schizophrenia disorders: perspectives from the spectrum

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

d,l-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The effect of lithium on impulsive aggressive behavior in man

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Effect of Lithium on Human Aggression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Borderline personality, opioids, and naltrexone

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

EEG theta activity and pain insensitivity in self-injurious borderline patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A voxel-based morphometric MRI study in female patients with borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Serotonergic function and self-injurious behavior in personality disorder patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Lithium Carbonate in Emotionally Unstable Character Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The prevention of recurrent suicidal acts

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Pharmacological prevention of suicidal behaviour

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Blunted hormone responses to Ipsapirone are associated with trait impulsivity in personality disorder patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Visual-spatial learning and memory in schizotypal personality disorder: continued evidence for the importance of working memory in the schizophrenia spectrum

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Dysregulation of regional endogenous opioid function in borderline personality disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Attentional mechanisms of borderline personality disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000071

7 January 2021

The Japanese journal of psychiatry and neurology

2

47

37

Ogiso

1993

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

24 November 2024

11

43

148

Leone

1982

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

24 November 2024

76

56

569

Fahlen

1995

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

Some Forms of Emotional Disturbance and their Relationship to Schizophrenia

24 November 2024

series ordinal

79

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

Behavioral and Brain Sciences

24 November 2024

80

28

313

Depue

2005

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

24 November 2024

122

40

70

Lion

1979

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

Psychopharmacology Bulletin

24 November 2024

142

23

177

Soloff

1987

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

Psychopharmacology Bulletin

24 November 2024

144

22

177

Soloff

1986

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

24 November 2024

166

57

233

Roth

1996

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

International Clinical Psychopharmacology

24 November 2024

182

24

270

Reich

2009

1 reference

https://api.crossref.org/works/10.1017/S1461145711000071

24 November 2024

Identifiers

1 reference

release_szhte7gfw5gitjeu37juxfau74

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/szhte7gfw5gitjeu37juxfau74

24 November 2022

mapped directly with Wikidata item

1 reference